This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Zhu, B.-q. Articles by Parmley, W. W Search for Related Content PubMed PubMed Citation Articles by Zhu, B.-q. Articles by Parmley, W. W Social Bookmarking                         What's this?

Effects of different durations of pretreatment with losartan on myocardial infarct size, endothelial function, and vascular endothelial growth factor

Division of Cardiology, Department of Medicine, University of California, San Francisco, USA

Yi-ping Sun

Division of Cardiology, Department of Medicine, University of California, San Francisco, USA

Richard E Sievers

Division of Cardiology, Department of Medicine, University of California, San Francisco, USA

Amanda EM Browne

Division of Cardiology, Department of Medicine, University of California, San Francisco, USA

Randall J Lee

Division of Cardiology, Department of Medicine, University of California, San Francisco, USA

Kanu Chatterjee

Division of Cardiology, Department of Medicine, University of California, San Francisco, USA

William W Parmley

Division of Cardiology, Department of Medicine, University of California, San Francisco, USA, parmley@ medicine.ucsf.edu

A previous study by our group showed that 10 weeks of pretreatment with losartan reduced myocardial infarct size and arrhythmias in a rat model of ischaemia-reperfusion. However, the effect of a differing time course of pretreatment has not been investigated. 104 Sprague-Dawley rats were randomised to four groups: a control, and three treatment groups in which losartan (40 mg/kg/day) was administered in drinking water for one day, one week, and four weeks respectively. After different durations of pretreatment, the rats were subjected to 17 minutes of left coronary artery occlusion and 120 minutes of reperfusion. Haemodynamic variables were not significantly different between the four groups. Myocardial infarct size was unchanged after one day and one week of pretreatment (52±7, 57±6% vs. control 55±3%), but was significantly reduced by four weeks of pretreatment with losartan (38±6, p<0.05). Endothelial-dependent vasorelaxation was significantly increased by four weeks of pretreatment (-81±4 vs. -62±7%, p<0.05). As an indicator of ischaemia, vascular endothelial growth factor (VEGF) levels in ischaemic myocardium were decreased after one and four weeks of pretreatment (0.75±0.05, 0.58±0.10 vs. 1.0, p<0.05, 0.01, respectively).

In conclusion, losartan has time-dependent cardiovascular protective effects. Four weeks of pretreatment with losartan decreased infarct size and VEGF, and improved endothelial dysfunction.

Key Words: angiotensin type 1 (AT1)-receptor antagonist • myocardial infarct size • ischaemia-reperfusion • endothelial function • VEGF (vascular endothelial growth factor)

Journal of Renin-Angiotensin-Aldosterone System, Vol. 2, No. 2, 129-133 (2001)
DOI: 10.3317/jraas.2001.014


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Pourdjabbar, T. G. Parker, Q. T. Nguyen, J.-F. Desjardins, N. Lapointe, J. N. Tsoporis, and J.-L. Rouleau Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: effect of dose on survival, ventricular arrhythmias, function, and remodeling Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1997 - H2005. [Abstract] [Full Text] [PDF]

				R. P.E. van Dokkum, W. B.A. Eijkelkamp, A. C.A. Kluppel, R. H. Henning, H. van Goor, M. Citgez, W. A.K.M. Windt, D. J. van Veldhuisen, P. A. de Graeff, and D. de Zeeuw Myocardial Infarction Enhances Progressive Renal Damage in an Experimental Model for Cardio-Renal Interaction J. Am. Soc. Nephrol., December 1, 2004; 15(12): 3103 - 3110. [Abstract] [Full Text] [PDF]

				K. L. Christman, A. J. Vardanian, Q. Fang, R. E. Sievers, H. H. Fok, and R. J. Lee Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium J. Am. Coll. Cardiol., August 4, 2004; 44(3): 654 - 660. [Abstract] [Full Text] [PDF]